MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
05 Setembro 2024 - 5:05PM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, today announced Company
management will participate at the Virtual Craig-Hallum Capital
Group Bioprocessing Conference on Thursday, September 19th at 9:30
am ET.
A replay link of the event will be available
following the conference on the “Events” section of the MaxCyte
investor relations website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients’
lives. We have spent more than 20 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today’s processes to
innovate tomorrow’s solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation® technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
US Media RelationsSpectrum Seismic
CollaborativeAnya Bolshemabolshem@spectrumscience.com
Nominated Adviser and Joint Corporate
BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate
BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserICR
ConsiliumMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
MaxCyte (NASDAQ:MXCT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
MaxCyte (NASDAQ:MXCT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
